Evidence map›Paper›PMID 24835496›Full record

ReviewExpert opinion on biological therapy2014

The future potential for cocaine vaccines.

Frank M Orson, Rongfu Wang, Stephen Brimijoin, Berma M Kinsey, Rana Ak Singh, Muthu Ramakrishnan, Helen Y Wang, Thomas R Kosten

Abstract readReview
In one paragraph

Review in Expert opinion on biological therapy, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
3.0field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 46 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 6 institutions in 1 country.

Frank M OrsonCenter for Translational Research in Inflammatory Diseases, Baylor College of Medicine, Department of Medicine , Bldg. 109, Rm. 234, 2002 Holcombe Blvd, Houston, TX 77030 , USA +1 713 794 7960 ; +1 713 794 7938 ; forson@bcm.edu.
Rongfu Wang
Stephen Brimijoin
Berma M Kinsey
Rana Ak Singh
Muthu Ramakrishnan
Helen Y Wang
Thomas R Kosten
Baylor College of Medicine · USHouston Methodist · USMayo Clinic · USMethodist Hospital · USUnited States Department of Veterans Affairs · USVeterans Health Administration · US

Funding

Human methamphetamine vaccine: Translational Avante Garde AwardDP1DA033502 · NIDA · BAYLOR COLLEGE OF MEDICINE · PI KOSTEN, THOMAS RICHARD · 2011 to 2015
$4.0M
Cocaine hydrolase gene therapy for cocaine abuse (DPI)DP1DA031340 · NIDA · MAYO CLINIC ROCHESTER · PI BRIMIJOIN, WILLIAM STEPHEN · 2010 to 2014
$3.9M
Development of a Human Hydrolase to Treat Cocaine Abuse and Overdose:Rat ModelsR01DA023979 · NIDA · MAYO CLINIC ROCHESTER · PI BRIMIJOIN, WILLIAM STEPHEN · 2007 to 2011
$2.3M
Multisite Controlled Trial of Cocaine Vaccine (1of 6) Lead Site/ Houston TreatmenR01DA025223 · NIDA · BAYLOR COLLEGE OF MEDICINE · PI KOSTEN, THOMAS RICHARD · 2008 to 2012
$1.7M
Cocaine Vaccine for Methadone Maintained PatientsR01DA015477 · NIDA · YALE UNIVERSITY · PI ROUNSAVILLE, BRUCE · 2002 to 2006
$1.7M
Development of Novel Vaccines for Cocaine AbuseR01DA030338 · NIDA · METHODIST HOSPITAL RESEARCH INSTITUTE · PI ORSON, FRANK M, WANG, RONGFU · 2010 to 2014
$1.6M
Cocaine Vaccines: Antibody and Affinity Measurement in SerumR21DA035591 · NIDA · BAYLOR COLLEGE OF MEDICINE · PI MUTHU, RAMAKRISHNAN · 2013 to 2014
$391k
NIDA NIH HHS DP1 DA031340NIDA NIH HHS DP1 DA033502NIDA NIH HHS R01 DA015477NIDA NIH HHS R01 DA023979NIDA NIH HHS R01 DA025223NIDA NIH HHS R01 DA030338NIDA NIH HHS R21 DA035591
6 · The paper itself

Abstract

introductionAddiction to cocaine is a major problem around the world, but especially in developed countries where the combination of wealth and user demand has created terrible social problems. Although only some users become truly addicted, those who are often succumb to a downward spiral in their lives from which it is very difficult to escape. From the medical perspective, the lack of effective and safe, non-addictive therapeutics has instigated efforts to develop alternative approaches for treatment, including anticocaine vaccines designed to block cocaine's pharmacodynamic effects. AREAS COVERED: This paper discusses the implications of cocaine pharmacokinetics for robust vaccine antibody responses, the results of human vaccine clinical trials, new developments in animal models for vaccine evaluation, alternative vaccine formulations and complementary therapy to enhance anticocaine effectiveness. EXPERT OPINION: Robust anti-cocaine antibody responses are required for benefit to cocaine abusers, but since any reasonably achievable antibody level can be overcome with higher drug doses, sufficient motivation to discontinue use is also essential so that the relative barrier to cocaine effects will be appropriate for each individual. Combining a vaccine with achievable levels of an enzyme to hydrolyze cocaine to inactive metabolites, however, may substantially increase the blockade and improve treatment outcomes.

Indexed as

AnimalsAntibodiesClinical Trials as TopicCocaineCocaine-Related DisordersHumansImmunotherapyProtein BindingVaccinesAntibodiesCocaineVaccinesaddictionadjuvantantibodybutyrylcholinesterasecocainegene therapyhydrolasevaccine

Identifiers

PMID24835496
PMCPMC4154474
OpenAlexW2070838711

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.